☆ 4.7 Editorial Material

Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape

EUROPEAN HEART JOURNAL (2022)

Journal

EUROPEAN HEART JOURNAL

Volume 43, Issue 41, Pages 4227-4228

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/eurheartj/ehac502

Keywords

-

Categories

Cardiac & Cardiovascular Systems

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis

Sang-Hyup Lee, Yong -Joon Lee, Jung Ho Heo, Seung-Ho Hur, Hyun Hee Choi, Kyung-Jin Kim, Ju Han Kim, Keun-Ho Park, Jung Hee Lee, Yu Jeong Choi, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim

Summary: This study compared the cardiovascular effects and tolerability of combination therapy with moderate-intensity statins and ezetimibe versus high-intensity statin monotherapy in elderly patients. The results showed no significant difference in the occurrence of cardiovascular events between the two treatment groups among patients aged ≥75 years and <75 years, but the combination therapy group had lower rates of adverse reactions. Therefore, combination therapy with moderate-intensity statins and ezetimibe has similar cardiovascular effects and greater tolerability in elderly patients.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial

Yong-Joon Lee, Jae Young Cho, Seng Chan You, Yong-Ho Lee, Kyeong Ho Yun, Yun-Hyeong Cho, Won-Yong Shin, Sang Wook Im, Woong Chol Kang, Yongwhi Park, Sung Yoon Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim

Summary: This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy among patients with diabetes mellitus and atherosclerotic cardiovascular disease. The study found that the combination therapy had similar outcomes in terms of cardiovascular events compared to the monotherapy, but had a higher rate of intolerance-related discontinuation or dose reduction. However, the combination therapy was more effective in achieving lower LDL cholesterol levels.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Medicine, General & Internal

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Byeong-Keuk Kim, Sung-Jin Hong, Yong-Joon Lee, Soon Jun Hong, Kyeong Ho Yun, Bum-Kee Hong, Jung Ho Heo, Seung-Woon Rha, Yun-Hyeong Cho, Seung-Jun Lee, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong

Summary: Through a randomized trial, it was found that the combination therapy of moderate-intensity statin and ezetimibe is as effective as high-intensity statin monotherapy in reducing cardiovascular events and maintaining stable LDL cholesterol concentrations, with better drug tolerance.

LANCET (2022)

Add to Collection

Article Endocrinology & Metabolism

Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial

Yong-Joon Lee, Sang-Hyup Lee, Seng Chan You, Yong-ho Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim

Summary: The study evaluated the safety and efficacy of a moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome (MetS) and atherosclerotic cardiovascular disease. The combination therapy showed comparable cardiovascular benefits with lower drug intolerance and low-density lipoprotein cholesterol levels compared to monotherapy, but no significant difference in new-onset diabetes.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Multidisciplinary Sciences

Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies

Young-Mi Ah, Minseob Jeong, Hye Duck Choi

Summary: This study found that low/moderate-intensity statin plus ezetimibe combination therapy is more effective and safer than high-intensity statin monotherapy in reducing lipid parameters and hs-CRP. It suggests that adding ezetimibe to statin should be preferred over increasing statin dose, and caution should be exercised when using high-intensity statin, especially in patients with related risks.

PLOS ONE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease A Post Hoc Analysis From the RACING Randomized Clinical Trial

Seung-Jun Lee, Jung-Joon Cha, Woong Gil Choi, Wang-Soo Lee, Jin-Ok Jeong, Seonghoon Choi, Yoon-Haeng Cho, Woojung Park, Chang-Hwan Yoon, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Soon Jun Hong, Jung-Sun Kim

Summary: The study aimed to evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in patients with very high risk (VHR) and non-VHR of atherosclerotic cardiovascular disease (ASCVD). The results showed no significant difference in the primary end point between combination therapy and high-intensity statin monotherapy in both VHR and non-VHR patients. Additionally, the combination therapy group had significantly lower levels of low-density lipoprotein cholesterol (LDL-C) compared to the high-intensity statin group, and was associated with greater changes in LDL-C levels and a higher proportion of patients with LDL-C levels below 70 mg/dL. The discontinuation or dose reduction of lipid-lowering drugs due to intolerance occurred less frequently in the combination therapy group.

JAMA CARDIOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease A Post Hoc Analysis From the RACING Randomized Clinical Trial

Seung-Jun Lee, Jung-Joon Cha, Woong Gil Choi, Wang-Soo Lee, Jin-Ok Jeong, Seonghoon Choi, Yoon-Haeng Cho, Woojung Park, Chang-Hwan Yoon, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Soon Jun Hong, Jung-Sun Kim, RACING Investigators

Summary: The study aimed to evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in patients with high-risk and non-high-risk atherosclerotic cardiovascular disease (ASCVD). The results showed that there was no significant difference in the primary endpoint between combination therapy and high-intensity statin monotherapy in both VHR and non-VHR patients. Furthermore, the combination therapy reduced low-density lipoprotein cholesterol levels and decreased the occurrence of drug intolerance.

JAMA CARDIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation

Minyoung Oh, Hyunji Kim, Eon Woo Shin, Changhwan Sung, Do-Hoon Kim, Dae Hyuk Moon, Ji Sung Lee, Pil Hyung Lee, Seung-Whan Lee, Cheol Whan Lee

Summary: The study compared the effects of statin/ezetimibe combination therapy and statin monotherapy on carotid atherosclerotic plaque inflammation, finding that both treatments were similarly effective in reducing inflammation and improving lipid levels.

MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Bom Lee, Sung-Jin Hong, Seung-Woon Rha, Jung Ho Heo, Seung-Ho Hur, Hyun Hee Choi, Kyung-Jin Kim, Ju Han Kim, Hyun Kuk Kim, Ung Kim, Yu Jeong Choi, Yong-Joon Lee, Seung-Jun Lee, Chul-Min Ahn, Young-Guk Ko, Byeong-Keuk Kim, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim

Summary: The combination therapy of moderate-intensity statin plus ezetimibe showed consistent effectiveness in reducing cardiovascular outcomes for patients with atherosclerotic cardiovascular disease (ASCVD), regardless of their baseline low-density lipoprotein cholesterol (LDL-C) levels.

ATHEROSCLEROSIS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries

Michel Farnier, Raul D. Santos, Juan Cosin-Sales, Marat Ezhov, Jian Liu, Denis Granados, Serena Santoni, Irfan Khan, Alberico L. Catapano

Summary: According to the 2019 ESC/EAS guidelines, the use of statin, ezetimibe, and statin plus ezetimibe FDC treatment strategies can significantly reduce the incidence of major adverse cardiovascular events at the population level.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Review Chemistry, Medicinal

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights

Maya R. Chilbert, Dylan VanDuyn, Sara Salah, Collin M. Clark, Qing Ma

Summary: Cardiovascular disease is a leading cause of death worldwide. Managing cholesterol, particularly low-density lipoprotein, is an important method for preventing complications. Combination therapy with high-intensity rosuvastatin and ezetimibe has shown potential benefits in reducing cholesterol levels and preventing atherosclerosis.

DRUG DESIGN DEVELOPMENT AND THERAPY (2022)

Add to Collection

Article Multidisciplinary Sciences

Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks

Yu-Cheng Kao, Tien-Hsing Chen, Chi-Hung Liu, Jawl-Shan Hwang, Ching-Chung Hsiao, Yu-Sheng Lin, Chun-Tai Mao, Ming-Jui Hung, Yan-Rong Li

Summary: In patients with type 2 diabetes mellitus, the study found that Atorvastatin 40 mg and ezetimibe 10 mg/simvastatin 20 mg had similar reductions of low-density lipoprotein cholesterol and major cardiovascular outcomes. However, the Atorvastatin 40 group had lower risks of unstable angina, percutaneous coronary intervention, and coronary artery bypass grafting compared to the ezetimibe/simvastatin group. This suggests that the main driver for cardiovascular risk reductions is still LDL-C lowering.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Moderate Intensity Exercise Training Improves Skeletal Muscle Performance in Symptomatic and Asymptomatic Statin Users

Neeltje A. E. Allard, Lando Janssen, Thorben Aussieker, Anouk A. F. Stoffels, Richard J. Rodenburg, Willem J. J. Assendelft, Paul D. Thompson, Tim Snijders, Maria T. E. Hopman, Silvie Timmers

Summary: This study found that a moderate intensity exercise training program improved muscle performance, capillarization, and mitochondrial content in both symptomatic and asymptomatic statin users without worsening muscle symptoms.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of High-Intensity Rosuvastatin vs. Combination of Low-Intensity Rosuvastatin and Ezetimibe on HbA1c Levels in Patients without Diabetes: A Randomized IDEAL Trial

Jeongcheon Choe, Sun-Hack Lee, Jinhee Ahn, Hyewon Lee, Jun-Hyok Oh, Junghyun Choi, Hancheol Lee, Kwangsoo Cha, Jinsup Park

Summary: This study aimed to investigate the effects of combining low-intensity statins with ezetimibe on glycated hemoglobin (HbA1c) levels in patients without diabetes. The results showed that the combination therapy did not significantly differ from high-intensity statin therapy alone in terms of HbA1c levels after 12 weeks. This suggests that the combination of low-intensity statins with ezetimibe may not be an effective strategy for preventing HbA1c elevation in patients without diabetes.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users

Neeltje A. E. Allard, Lando Janssen, Bart Lagerwaard, Malou A. H. Nuijten, Coen C. W. G. Bongers, Richard J. Rodenburg, Paul D. Thompson, Thijs M. H. Eijsvogels, Willem J. J. Assendelft, Tom J. J. Schirris, Silvie Timmers, Maria T. E. Hopman

Summary: This study aimed to determine the effect of prolonged moderate-intensity exercise on markers of muscle injury in statin users and whether statin-associated muscle symptoms exacerbate this injury. The results showed that statin use and the presence of statin-associated muscle symptoms do not aggravate exercise-induced muscle injury, and there is no relationship between muscle injury markers and leukocyte CoQ10 levels.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Prevention of cardiorenal damage: importance of albuminuria

Luis M. Ruilope, Alberto Ortiz, Alejandro Lucia, Blanca Miranda, Gloria Alvarez-Llamas, Maria G. Barderas, Massimo Volpe, Gema Ruiz-Hurtado, Bertram Pitt

Summary: Chronic kidney disease (CKD) is a leading cause of death that requires early detection for effective management. The current diagnostic criteria for CKD only identify advanced stages, leaving a 'blind spot' in detection where kidney injury is present but undetectable. Elevated urinary albumin-excretion rate can predict future cardiovascular events. Implementing opportunistic or systematic albuminuria screening and therapy has the potential to improve cardiorenal outcomes and mitigate the projected burden of CKD and cardiovascular diseases in the future.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

A gender issue in the diagnostic imaging work-up of stable coronary artery disease? Insights from DISCHARGE

Rocco Vergallo, Massimo Volpe

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The promise of selective aldosterone synthase inhibition for the management of resistant hypertension

Massimo Volpe, Carlo Patrono

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges

Massimo Volpe, Carlo Patrono

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Endocrine functions of the heart: from bench to bedside

Massimo Volpe, Giovanna Gallo, Speranza Rubattu

Summary: The heart has an endocrine function, producing biologically active substances such as natriuretic peptides (NPs). NPs play important roles in regulating cardiovascular and renal systems through their interaction with guanylate cyclase-A coupled receptors. They also have potential therapeutic applications in treating heart failure and hypertension, and are used as biomarkers in cardiovascular diseases. Furthermore, research on the regulation of NP synthesis and secretion by microRNAs and epigenetics, as well as their interactions with other endocrine systems, is ongoing.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

What if flu vaccination is the most responsible thing to do for cardiovascular health in the upcoming season?

Massimo Volpe, Allegra Battistoni

EUROPEAN HEART JOURNAL SUPPLEMENTS (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The promise of a new orally active body weight reducer

Massimo Volpe, Daniela Pedicino

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

New evidence supporting haemodynamics-guided remote management of congestion in heart failure

Daniela Pedicino, Massimo Volpe

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Artificial intelligence in echocardiography: a better alternative to the human eye?

Leonarda Galiuto, Massimo Volpe

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Atrial fibrillation ablation improves outcomes in patients with end-stage heart failure: is it all gold the glitter in the CASTLE?

Daniela Pedicino, Massimo Volpe

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The revolution of beat-to-beat wireless bidirectional communication between intra-cardiac devices

Maria Lucia Narducci, Massimo Volpe

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Light the FIRE of revascularization in older patients with myocardial infarction

Rocco Vergallo, Massimo Volpe

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular risk and the COVID-19 pandemic: A retrospective observational study in a population of healthcare professionals

G. Solfanelli, D. Giaccio, A. Tropea, V. Bucicovschi, G. Gallo, G. Tocci, B. Musumeci, L. Marcellini, E. Barbato, M. Volpe, A. Battistoni

Summary: To contain the spread of COVID-19, many countries implemented restrictive measures, which led to significant changes in daily behaviors. Healthcare workers, who faced increased risk of infection, might have experienced additional stress and developed unhealthy habits. This study investigated the impact of the pandemic on cardiovascular risk in a population of healthy healthcare workers using the SCORE-2 assessment.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2023)

Add to Collection

Article Peripheral Vascular Disease

An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention

Giovanna Gallo, Riccardo Sarzani, Arrigo Francesco Giuseppe Cicero, Stefano Genovese, Matteo Pirro, Luca Gallelli, Andrea Faggiano, Massimo Volpe

Summary: Current cardiovascular disease prevention strategies focus on managing individual cardiovascular risk profiles, often requiring patients to take multiple drugs. Single pill fixed dose combinations can improve blood pressure and cholesterol control compared to separate drug administration, due to better adherence and simplicity. This paper discusses the use of the Rosuvastatin-Amlodipine combination for managing hypertension/hypercholesterolemia and emphasizes the importance of early and effective cardiovascular risk management.

HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2023)

Add to Collection

Review Peripheral Vascular Disease

The Emerging Role of Prediabetes and Its Management: Focus on l-Arginine and a Survey in Clinical Practice

Massimo Volpe, Armando Ferrera, Roberto Piccinocchi, Carmine Morisco

Summary: The worldwide increase in metabolic disorders has led to interest in early identification and management of high-risk patients, especially prediabetes. Lifestyle modification and pharmacotherapy, including metformin, vitamin D, and l-arginine, have shown potential benefits in preventing the progression to type 2 diabetes. This review focuses on the role of l-arginine in prediabetes, including its molecular mechanisms and ongoing trials, and reports interesting data from clinical practice in Italy.

HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.